Apimeds Pharmaceuticals US APUS
NYSE APUS
$4.41 +0.02 (+0.34%)
At close: Aug 20, 2026 · 10:51 AM UTC

Apimeds Pharmaceuticals US (APUS) Consolidated Net Income (2024 - 2025)

Apimeds Pharmaceuticals US's (APUS) quarterly Consolidated Net Income came in at -$7.3 million in Q4 2025, down 1797.17% YoY from $429099.8 in Q4 2024, and down 305.91% on a QoQ basis from -$1.8 million in Q3 2025.

Apimeds Pharmaceuticals US (APUS) Consolidated Net Income (2024 - 2025) Analysis & Trends

Apimeds Pharmaceuticals US (APUS) has 2 years of Consolidated Net Income data on file, last reported at -$7.3 million in Q4 2025.

  • Quarterly Consolidated Net Income fell 1797.17% year-over-year to -$7.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$12.2 million (down 730.98% YoY) and the FY2025 annual result came in at -$14.5 million, down 498.81% from the prior year.
  • Consolidated Net Income fell to -$7.3 million in Q4 2025, from -$1.8 million in the prior quarter.
  • In the past five years, Consolidated Net Income ranged from a high of -$296473.0 in Q1 2024 to a low of -$7.3 million in Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Consol Net Inc. (Qtr)
1 Haleon 43.76 Bn 42.79 Bn - -
2 Teva Pharmaceutical Industries 43.38 Bn 39.73 Bn 2.15 Bn -576.00 Mn
3 Zoetis 31.61 Bn 29.93 Bn 1.05 Bn 866.00 Mn
4 Takeda Pharmaceutical 28.64 Bn 22.84 Bn 5.10 Bn 1.33 Bn
5 United Therapeutics 22.20 Bn 19.54 Bn 683.80 Mn 333.00 Mn
6 Viatris 18.82 Bn 17.93 Bn 1.46 Bn -118.80 Mn
7 Neurocrine Biosciences 15.67 Bn 15.28 Bn 935.80 Mn 144.40 Mn
8 Elanco Animal Health 12.11 Bn 11.58 Bn 798.00 Mn 54.00 Mn
9 Dr Reddys Laboratories 10.10 Bn 9.94 Bn - -
10 Apimeds Pharmaceuticals US 7.55 Mn 7.55 Mn - -9.48 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 -7.28 Mn
Sep 30, 2025 -1.79 Mn
Jun 30, 2025 -2.67 Mn
Mar 31, 2025 -402,397.00
Dec 31, 2024 -383,864.00
Sep 30, 2024 -332,521.00
Jun 30, 2024 -449,363.00
Mar 31, 2024 -296,473.00